Investigation of Biomarkers in Susac Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01273792|
Recruitment Status : Recruiting
First Posted : January 11, 2011
Last Update Posted : November 29, 2018
|Condition or disease|
Susac Syndrome is a rare disease characterized by encephalopathy, branch retinal artery occlusion and sensorineural deafness. The pathogenesis is not yet clear, an autoimmune endotheliopathy is discussed. Because of the variable and often incomplete clinical presentation, the establishment of the diagnosis is often delayed or even completely missed.
The aim of this study is to identify biomarkers that facilitate the reliable and prompt establishment of the diagnosis. Patients with a definite diagnosis of Susac syndrome and healthy subjects as controls are investigated.
Furthermore, the correlation of serological markers with structural retinal and cerebral changes will contribute to clarification of the pathogenesis of Susac syndrome.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Investigation of Relevant Biomarkers in Patients With Susac Syndrome|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
|Patients with Susac syndrome|
|Matched healthy controls|
- disease specific patterns of pathology on cranial MRIone-time cranial MRI
- disease specific patterns of pathology in optical coherence tomographyone time optical coherence tomography
- serological biomarkers [ Time Frame: not defined, cross-sectional analysis ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273792
|Contact: Jan M Dörr, MD||+49 30 450 ext email@example.com|
|NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin||Recruiting|
|Berlin, Germany, 10117|
|Contact: Jan M Dörr, MD +49 30 450 ext 660162 firstname.lastname@example.org|
|Principal Investigator: Jan M Dörr, MD|
|Principal Investigator:||Jan M Dörr, MD||NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin|